Lyka Labs Ltd
NSE:LYKALABS
Lyka Labs Ltd
NSE:LYKALABS
Price:
68.02
INR
-1.51%
Market Closed
Market Cap:
₹2.4B
Relative Value
The Relative Value of one
LYKALABS
stock under the Base Case scenario is
126.49
INR.
Compared to the current market price of 68.02 INR,
Lyka Labs Ltd
is
Undervalued by 46%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
LYKALABS
Relative Value
Base Case
126.49
INR
Undervaluation 46%
Multiples Across Competitors
LYKALABS Competitors Multiples
Lyka Labs Ltd Competitors
Lyka Labs Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Lyka Labs Ltd
NSE:LYKALABS
|
2.4B INR | 1.8 | 118.1 | 24.4 | 87.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD | 15.1 | 47.8 | 32.2 | 34.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
584.7B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
291.9B CHF | 4.8 | 31.1 | 13.1 | 15.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.4B GBP | 5.6 | 32.1 | 17.7 | 24.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
246.5B CHF | 5.6 | 22.7 | 14 | 17.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.7B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.5 | 13.4 | 9.8 | 11.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.8B USD | 2.5 | 20 | 7.4 | 10 | |
| UK |
|
GSK plc
XETRA:GS71
|
104B EUR | 2.8 | 15.8 | 8 | 11.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
